SCYNEXIS, Inc. (SCYX): Price and Financial Metrics
SCYNEXIS, Inc. (SCYX)
Today's Latest Price: $0.90 USD
0.02 (2.51%)
Updated Jun 5 8:59am
Add SCYX to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 214 in Medical - Pharmaceuticals
See all "A" rated Strong Buy stocks
SCYX Stock Summary
- With a price/sales ratio of 1,518.59, Scynexis Inc has a higher such ratio than 99.61% of stocks in our set.
- Revenue growth over the past 12 months for Scynexis Inc comes in at -77.73%, a number that bests merely 1.7% of the US stocks we're tracking.
- Scynexis Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -50.63%, greater than the shareholder yield of only 8.01% of stocks in our set.
- Stocks that are quantitatively similar to SCYX, based on their financial statements, market capitalization, and price volatility, are MRSN, TOCA, CBMG, ITCI, and ADAP.
- SCYX's SEC filings can be seen here. And to visit Scynexis Inc's official web site, go to www.scynexis.com.
SCYX Daily Price Range
SCYX 52-Week Price Range
SCYX Stock Price Chart More Charts
SCYX Price/Volume Stats
| Current price | $0.90 | 52-week high | $1.44 |
| Prev. close | $0.88 | 52-week low | $0.50 |
| Day low | $0.90 | Volume | 24,921 |
| Day high | $0.90 | Avg. volume | 1,092,509 |
| 50-day MA | $0.85 | Dividend yield | N/A |
| 200-day MA | $0.96 | Market Cap | 88.93M |
SCYNEXIS, Inc. (SCYX) Company Bio
SCYNEXIS, Inc., a pharmaceutical company, develops and commercializes novel anti-infectives to address unmet therapeutic needs. Its lead product candidate includes SCY-078, which is in Phase I clinical trials of the intravenous formulation; Phase II clinical trials for the treatment of invasive candida infections; and Phase II clinical trials for unmet medical needs, such as vulvovaginal candidiasis. The company was founded in 1999 and is based in Jersey City, New Jersey.
Loading social stream, please wait...